Investing.com UK - Financial Markets Worldwide
NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction

Published 27/09/2022, 14:35
© Reuters. Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction
AQST
-

  • Aquestive Therapeutics Inc (NASDAQ: AQST) announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film.
  • The trial was designed to compare single doses of AQST-109 to EpiPen 0.3mg and epinephrine 0.3mg intramuscular (IM) injection and repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection.
  • EpiPen auto-injectors are used for allergic emergencies.
  • Related: Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allergies.
  • Single dose administration showed AQST-109 achieved a significantly faster Tmax (12 minutes) compared to both EpiPen (22.5 minutes) and epinephrine 0.3mg IM injection (45 minutes).
  • AQST-109 repeat dosing provided significantly higher drug plasma concentrations, with a Tmax of 8 minutes after administration, and extensive absorption was observed.
  • After one dose of AQST-109, maximum mean effects on systolic blood pressure occurred within 5 minutes of dosing compared to 8 minutes for EpiPen. Maximum mean effects in heart rate occurred within 8 minutes of administering AQST-109 compared to an average of 5 minutes within administering EpiPen.
  • Safety results for AQST-109 were in line with expectations, and no severe or serious adverse events were reported.
  • End-of-Phase 2 meeting with FDA is scheduled for the fourth quarter of 2022, and the remaining clinical studies will commence after that.
  • Price Action: AQST shares are up 8.88% at $1.21 during the market session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.